On Friday, 18 November, the European Commission announced that the Health Emergency Preparedness and Response Authority (HERA) had signed a joint procurement framework contract with biotechnology company Bavarian Nordic A/S for the delivery of Imvanex, a third-generation monkeypox vaccine (see EUROPE 12998/24).
The framework contract provides participating countries the option to receive delivery of up to 2 million doses of monkeypox vaccine in 2023 and 2024. The European Commission specifies that these vaccines are intended to cover participating [Member] States’ medium- and long-term needs.
Fourteen countries are participating in this joint procurement. The first deliveries are expected to be made in the second quarter of 2023.
This contract complements the purchases that the European Health and Digital Executive Agency made for HERA—purchases that aimed to meet Member States’ more urgent needs (see EUROPE 12995/35). (Original version in French by Émilie Vanderhulst)